IBDEI15Y ; ; 01-FEB-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,18883,1,3,0)
;;=3^Sicca Syndrome w/ Myopathy
;;^UTILITY(U,$J,358.3,18883,1,4,0)
;;=4^M35.03
;;^UTILITY(U,$J,358.3,18883,2)
;;=^5011789
;;^UTILITY(U,$J,358.3,18884,0)
;;=M35.09^^64^841^57
;;^UTILITY(U,$J,358.3,18884,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18884,1,3,0)
;;=3^Sicca Syndrome w/ Oth Organ Involvement
;;^UTILITY(U,$J,358.3,18884,1,4,0)
;;=4^M35.09
;;^UTILITY(U,$J,358.3,18884,2)
;;=^5011791
;;^UTILITY(U,$J,358.3,18885,0)
;;=M35.04^^64^841^58
;;^UTILITY(U,$J,358.3,18885,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18885,1,3,0)
;;=3^Sicca Syndrome w/ Tubulo-Interstitial Nephropathy
;;^UTILITY(U,$J,358.3,18885,1,4,0)
;;=4^M35.04
;;^UTILITY(U,$J,358.3,18885,2)
;;=^5011790
;;^UTILITY(U,$J,358.3,18886,0)
;;=M35.00^^64^841^59
;;^UTILITY(U,$J,358.3,18886,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18886,1,3,0)
;;=3^Sicca Syndrome,Unspec
;;^UTILITY(U,$J,358.3,18886,1,4,0)
;;=4^M35.00
;;^UTILITY(U,$J,358.3,18886,2)
;;=^5011786
;;^UTILITY(U,$J,358.3,18887,0)
;;=M32.10^^64^841^62
;;^UTILITY(U,$J,358.3,18887,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18887,1,3,0)
;;=3^Systemic Lupus Erythematosus,Unspec Organ/System Involvement
;;^UTILITY(U,$J,358.3,18887,1,4,0)
;;=4^M32.10
;;^UTILITY(U,$J,358.3,18887,2)
;;=^5011753
;;^UTILITY(U,$J,358.3,18888,0)
;;=M32.9^^64^841^61
;;^UTILITY(U,$J,358.3,18888,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18888,1,3,0)
;;=3^Systemic Lupus Erythematosus,Unspec
;;^UTILITY(U,$J,358.3,18888,1,4,0)
;;=4^M32.9
;;^UTILITY(U,$J,358.3,18888,2)
;;=^5011761
;;^UTILITY(U,$J,358.3,18889,0)
;;=M34.2^^64^841^63
;;^UTILITY(U,$J,358.3,18889,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18889,1,3,0)
;;=3^Systemic Sclerosis Induced by Drug/Chemical
;;^UTILITY(U,$J,358.3,18889,1,4,0)
;;=4^M34.2
;;^UTILITY(U,$J,358.3,18889,2)
;;=^5011780
;;^UTILITY(U,$J,358.3,18890,0)
;;=M34.81^^64^841^64
;;^UTILITY(U,$J,358.3,18890,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18890,1,3,0)
;;=3^Systemic Sclerosis w/ Lung Involvement
;;^UTILITY(U,$J,358.3,18890,1,4,0)
;;=4^M34.81
;;^UTILITY(U,$J,358.3,18890,2)
;;=^5011781
;;^UTILITY(U,$J,358.3,18891,0)
;;=M34.82^^64^841^65
;;^UTILITY(U,$J,358.3,18891,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18891,1,3,0)
;;=3^Systemic Sclerosis w/ Myopathy
;;^UTILITY(U,$J,358.3,18891,1,4,0)
;;=4^M34.82
;;^UTILITY(U,$J,358.3,18891,2)
;;=^5011782
;;^UTILITY(U,$J,358.3,18892,0)
;;=M34.83^^64^841^66
;;^UTILITY(U,$J,358.3,18892,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18892,1,3,0)
;;=3^Systemic Sclerosis w/ Polyneuropathy
;;^UTILITY(U,$J,358.3,18892,1,4,0)
;;=4^M34.83
;;^UTILITY(U,$J,358.3,18892,2)
;;=^5011783
;;^UTILITY(U,$J,358.3,18893,0)
;;=M34.9^^64^841^67
;;^UTILITY(U,$J,358.3,18893,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18893,1,3,0)
;;=3^Systemic Sclerosis,Unspec
;;^UTILITY(U,$J,358.3,18893,1,4,0)
;;=4^M34.9
;;^UTILITY(U,$J,358.3,18893,2)
;;=^5011785
;;^UTILITY(U,$J,358.3,18894,0)
;;=J84.170^^64^841^16
;;^UTILITY(U,$J,358.3,18894,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18894,1,3,0)
;;=3^Interstitial Lung Dis w/ Progressive Fibrotic Phenotype in Dis Classd Elsewhere
;;^UTILITY(U,$J,358.3,18894,1,4,0)
;;=4^J84.170
;;^UTILITY(U,$J,358.3,18894,2)
;;=^5159208
;;^UTILITY(U,$J,358.3,18895,0)
;;=J84.178^^64^841^17
;;^UTILITY(U,$J,358.3,18895,1,0)
;;=^358.31IA^4^2
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI15Y 3770 printed Apr 09, 2024@21:45:11 Page 2
IBDEI15Y ; ; 01-FEB-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,18883,1,3,0)
+2 ;;=3^Sicca Syndrome w/ Myopathy
+3 ;;^UTILITY(U,$J,358.3,18883,1,4,0)
+4 ;;=4^M35.03
+5 ;;^UTILITY(U,$J,358.3,18883,2)
+6 ;;=^5011789
+7 ;;^UTILITY(U,$J,358.3,18884,0)
+8 ;;=M35.09^^64^841^57
+9 ;;^UTILITY(U,$J,358.3,18884,1,0)
+10 ;;=^358.31IA^4^2
+11 ;;^UTILITY(U,$J,358.3,18884,1,3,0)
+12 ;;=3^Sicca Syndrome w/ Oth Organ Involvement
+13 ;;^UTILITY(U,$J,358.3,18884,1,4,0)
+14 ;;=4^M35.09
+15 ;;^UTILITY(U,$J,358.3,18884,2)
+16 ;;=^5011791
+17 ;;^UTILITY(U,$J,358.3,18885,0)
+18 ;;=M35.04^^64^841^58
+19 ;;^UTILITY(U,$J,358.3,18885,1,0)
+20 ;;=^358.31IA^4^2
+21 ;;^UTILITY(U,$J,358.3,18885,1,3,0)
+22 ;;=3^Sicca Syndrome w/ Tubulo-Interstitial Nephropathy
+23 ;;^UTILITY(U,$J,358.3,18885,1,4,0)
+24 ;;=4^M35.04
+25 ;;^UTILITY(U,$J,358.3,18885,2)
+26 ;;=^5011790
+27 ;;^UTILITY(U,$J,358.3,18886,0)
+28 ;;=M35.00^^64^841^59
+29 ;;^UTILITY(U,$J,358.3,18886,1,0)
+30 ;;=^358.31IA^4^2
+31 ;;^UTILITY(U,$J,358.3,18886,1,3,0)
+32 ;;=3^Sicca Syndrome,Unspec
+33 ;;^UTILITY(U,$J,358.3,18886,1,4,0)
+34 ;;=4^M35.00
+35 ;;^UTILITY(U,$J,358.3,18886,2)
+36 ;;=^5011786
+37 ;;^UTILITY(U,$J,358.3,18887,0)
+38 ;;=M32.10^^64^841^62
+39 ;;^UTILITY(U,$J,358.3,18887,1,0)
+40 ;;=^358.31IA^4^2
+41 ;;^UTILITY(U,$J,358.3,18887,1,3,0)
+42 ;;=3^Systemic Lupus Erythematosus,Unspec Organ/System Involvement
+43 ;;^UTILITY(U,$J,358.3,18887,1,4,0)
+44 ;;=4^M32.10
+45 ;;^UTILITY(U,$J,358.3,18887,2)
+46 ;;=^5011753
+47 ;;^UTILITY(U,$J,358.3,18888,0)
+48 ;;=M32.9^^64^841^61
+49 ;;^UTILITY(U,$J,358.3,18888,1,0)
+50 ;;=^358.31IA^4^2
+51 ;;^UTILITY(U,$J,358.3,18888,1,3,0)
+52 ;;=3^Systemic Lupus Erythematosus,Unspec
+53 ;;^UTILITY(U,$J,358.3,18888,1,4,0)
+54 ;;=4^M32.9
+55 ;;^UTILITY(U,$J,358.3,18888,2)
+56 ;;=^5011761
+57 ;;^UTILITY(U,$J,358.3,18889,0)
+58 ;;=M34.2^^64^841^63
+59 ;;^UTILITY(U,$J,358.3,18889,1,0)
+60 ;;=^358.31IA^4^2
+61 ;;^UTILITY(U,$J,358.3,18889,1,3,0)
+62 ;;=3^Systemic Sclerosis Induced by Drug/Chemical
+63 ;;^UTILITY(U,$J,358.3,18889,1,4,0)
+64 ;;=4^M34.2
+65 ;;^UTILITY(U,$J,358.3,18889,2)
+66 ;;=^5011780
+67 ;;^UTILITY(U,$J,358.3,18890,0)
+68 ;;=M34.81^^64^841^64
+69 ;;^UTILITY(U,$J,358.3,18890,1,0)
+70 ;;=^358.31IA^4^2
+71 ;;^UTILITY(U,$J,358.3,18890,1,3,0)
+72 ;;=3^Systemic Sclerosis w/ Lung Involvement
+73 ;;^UTILITY(U,$J,358.3,18890,1,4,0)
+74 ;;=4^M34.81
+75 ;;^UTILITY(U,$J,358.3,18890,2)
+76 ;;=^5011781
+77 ;;^UTILITY(U,$J,358.3,18891,0)
+78 ;;=M34.82^^64^841^65
+79 ;;^UTILITY(U,$J,358.3,18891,1,0)
+80 ;;=^358.31IA^4^2
+81 ;;^UTILITY(U,$J,358.3,18891,1,3,0)
+82 ;;=3^Systemic Sclerosis w/ Myopathy
+83 ;;^UTILITY(U,$J,358.3,18891,1,4,0)
+84 ;;=4^M34.82
+85 ;;^UTILITY(U,$J,358.3,18891,2)
+86 ;;=^5011782
+87 ;;^UTILITY(U,$J,358.3,18892,0)
+88 ;;=M34.83^^64^841^66
+89 ;;^UTILITY(U,$J,358.3,18892,1,0)
+90 ;;=^358.31IA^4^2
+91 ;;^UTILITY(U,$J,358.3,18892,1,3,0)
+92 ;;=3^Systemic Sclerosis w/ Polyneuropathy
+93 ;;^UTILITY(U,$J,358.3,18892,1,4,0)
+94 ;;=4^M34.83
+95 ;;^UTILITY(U,$J,358.3,18892,2)
+96 ;;=^5011783
+97 ;;^UTILITY(U,$J,358.3,18893,0)
+98 ;;=M34.9^^64^841^67
+99 ;;^UTILITY(U,$J,358.3,18893,1,0)
+100 ;;=^358.31IA^4^2
+101 ;;^UTILITY(U,$J,358.3,18893,1,3,0)
+102 ;;=3^Systemic Sclerosis,Unspec
+103 ;;^UTILITY(U,$J,358.3,18893,1,4,0)
+104 ;;=4^M34.9
+105 ;;^UTILITY(U,$J,358.3,18893,2)
+106 ;;=^5011785
+107 ;;^UTILITY(U,$J,358.3,18894,0)
+108 ;;=J84.170^^64^841^16
+109 ;;^UTILITY(U,$J,358.3,18894,1,0)
+110 ;;=^358.31IA^4^2
+111 ;;^UTILITY(U,$J,358.3,18894,1,3,0)
+112 ;;=3^Interstitial Lung Dis w/ Progressive Fibrotic Phenotype in Dis Classd Elsewhere
+113 ;;^UTILITY(U,$J,358.3,18894,1,4,0)
+114 ;;=4^J84.170
+115 ;;^UTILITY(U,$J,358.3,18894,2)
+116 ;;=^5159208
+117 ;;^UTILITY(U,$J,358.3,18895,0)
+118 ;;=J84.178^^64^841^17
+119 ;;^UTILITY(U,$J,358.3,18895,1,0)
+120 ;;=^358.31IA^4^2
